The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
FidiasP.M., DakhilS.R., LyssA.P.Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol.2008; 27(4): 591–598.
2.
HelbekkmoN., SundstromS.H., AaseboU.Vinorelbine/carboplatin vs. gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer.2007; 97(3): 283–289.
3.
GronbergB.H., BremnesR.M., FlottenO.Phase III study by the Norwegian Lung Cancer Study Group: peme-trexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol.2009; 27(19): 3217–3224.
4.
LeeS.M., RuddR., WollP.J.Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and carboplatin in advanced non-small-cell lung cancer. J Clin Oncol.2009; 27(31): 5248–5254.
5.
National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines – Non-Small Cell Lung Cancer. V.3. 2011. www.nccn.org. Accessed February 26, 2011.
6.
CheungY.W., CradockJ.C., VishnuvajjalaB.R., FloraK.P.Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions. Am J Hosp Pharm.1987; 44(1): 124–130.
7.
TemperoM., PlunkettW., Ruiz Van HaperenV.Randomized Phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol.2003; 21(18): 3402–3408.
8.
National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines - Antiemesis. V.3. 2011. http://www.nccn.org. Accessed February 26, 2011.
9.
KrisM.G., HeskethP.J., SomerfieldM.R.American Society of Clinical Oncology Guideline for Antiemetics in Oncology: update 2006. J Clin Oncol.2006; 24(18): 2932–2947.
GelingO., EichlerH.G.Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
12.
CornelisonT.L., ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol.1993; 50(2): 147–158.
ZanottiK.M., MarkhamM.Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Safety.2001; 24(10): 767–779.
15.
National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology - Myeloid Growth Factors. V.1.2010. http://www.nccn.org. Accessed February 26, 2011.
16.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49(9): 1796–1799.
17.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surg.1985; 75(3): 397–402.
18.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35(1): 57–74.
19.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
20.
WaddellJ.A., SolimandoD.A.Verifying carboplatin dose calculations in adult patients with the Calvert and modified Calvert formulas. Hosp Pharm.2000; 35(9): 914–922.
